

Please add the following new claims:

18. (New) Arrangement according to Patent Claim 3, characterized in that the implant has clinically effective geometrical properties and has the shape of a cylindrical or conical solid with an outer surface for direct contact with the body tissue (2).


19. (New) Arrangement according to Patent Claim 3, characterized in that the implant element consists of an absorbable collagen sponge.

20. (New) Arrangement according to Patent Claim 4, characterized in that the implant element consists of an absorbable collagen sponge.

#### REMARKS

The claims have been amended to eliminate multiple dependency and to improve their format. None of these amendments is believed to involve any new matter. Accordingly, it is respectfully requested that the foregoing amendments be entered, that the application as so amended receive an examination on the merits, and that the claims as now presented receive an early allowance.

Respectfully submitted,



Burton A. Amernick, Reg. No. 24,852  
Connolly Bove Lodge & Hutz LLP  
1990 M Street, N.W., Suite 800  
Washington, D.C. 20036-3425  
Telephone: 202-331-7111

Date: 11-30-01

## MARKED-UP REVISIONS

### IN THE CLAIMS:

4. (Amended) Arrangement according to Patent Claim 2 [or 3], characterized in that the implant has clinically effective geometrical properties and has the shape of a cylindrical or conical solid with an outer surface for direct contact with the body tissue (2).

5. (Amended) Arrangement according to Patent Claim 2, [3 or 4], characterized in that the implant element consists of an absorbable collagen sponge.

6. (Amended) Arrangement according to [any of Patent Claims 2 to 5] Claim 2, characterized in that the bioactive substance is a substance belonging to the superfamily TGF- $\beta$ .

7. (Amended) Arrangement according to [any of Patent Claims 2 to 6] Claim 2, characterized in that the implant or the implant element has a body part with a threaded outer surface and a conical tip, the said tip having an open section with an axial hole or recess for the said body, which hole or recess is open towards the end surface of the tip part, and one or more through-holes which communicate with the said axial holes and extend radially through the implant body part at right angles to the longitudinal implant axis in order to permit direct release of the bioactive substance from the said body through the said holes or openings.

8. (Amended) Arrangement according to [any of Patent Claims 2 to 7] Claim 2, characterized in that the axial hole extends from the tipped end part through the main part of the implant body in order to permit release of growth factors along the length of the implant body part through a suitable number of channels or recesses in the wall of the implant or implant element.

9. (Amended) Arrangement according [to any of Patent Claims 2 to 8] Claim 2, characterized in that the design(s) and structure(s) of the body or bodies are chosen on the basis of predetermined release functions.

10. (Amended) Arrangement according [to any of Patent Claims 2 to 9] Claim 2, characterized in that a first body assumes a first position in which the first body is arranged with a first degree of exposure of a certain substance, and a second body assumes a second position in which the second body has a second degree of exposure of the same substance, or of another substance, less than the first degree of exposure, or vice versa, for the purpose of permitting a controlled or optimum release function in the implant situation in question.

11. (Amended) Arrangement according to [any of Patent Claims 2 to 10] Claim 2, characterized in that each body is arranged in such a way that, in the said cooperation and release function, it varies the degree of release of bioactive substance and, for example, effects a greater degree of release at the start of the period than at the end of the period, or vice versa.

12. (Amended) Arrangement according to [any of Patent Claims 2 to 11] Claim 2, characterized in that the design(s) or extent(s) of the space or spaces and any associated channels or recesses are chosen on the basis of a predetermined or anticipated release function.

13. (Amended) Arrangement according to [any of Patent Claims 2 to 12] Claim 2, characterized in that the channels or recesses are arranged with different cross-sectional areas and/or extents, which means that different parts of the same body or different bodies are subject to different degrees of exposure in the release function, for the purpose of permitting a controlled or optimum release function for the bioactive substance or substances.

14. (Amended) Arrangement according to [any of Patent Claims 2 to 13] Claim 2, characterized in that two bodies are situated at a distance from each other in order to serve different parts of the surrounding bone and/or tissue structure.

15. (Amended) Arrangement according to [any of Patent Claims 2 to 14] Claim 2, characterized in that each implant with associated body/bodies can be built up or chosen from a number of implants which vary in respect of the spaces and any recesses and/or channels, and/or from a number of different bodies having different properties in respect of the release function and substances.

16. (Amended) Arrangement according to [any of Patent Claims 2 to 15] Claim 2, characterized in that each body can be introduced into the respective space and, after introduction, can be saturated with bioactive substance, for example by means of an injection needle or a hand pump.